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THESIS SUMMARY
Colitis, an inflammatory bowel disorder, is caused by an array of factors, including
luminal microbiota alterations and dysregulation of the immune system. Gut microbiota
produce indole, a compound thought to protect the colon from inflammatory damage. In
this paper, we explore the effect of indole-3-carbinol, a compound found in many
cruciferous vegetables, treatment on an ulcerative colitis mouse model with aryl
hydrocarbon receptor (AhR) depletion in Rorc-expressing immune cells. Indole-3-carbinol
has been proven to be a ligand for AhR receptors and to reduce inflammation in an
interleukin-22-dependent manner in female mice. This study explores the same theory but
with both female and male mice.
ABSTRACT
Colitis is an inflammatory bowel disorder (IBD) whose etiology is attributed to
modification in the luminal microbiota and dysregulation in the immune response. Indole
is a signaling molecule which is naturally produced by gut luminal microbiota. Indole-3carbinol (I3C) is a compound commonly found in vegetables and a ligand for the aryl
hydrocarbon receptor (AhR). Previous studies have detected decreased expression and
activation on the AhR receptor in colitis patients, thought to possibly alter gut microbiota
metabolism, subsequently promoting colitis. 1 AhR, expressed in a variety of immune and
epithelial cells, contributes to gut homeostasis by affecting vital mediators such as
regulatory T cell (Treg)/T helper 17 (Th17), colonic epithelial cell (CEC)- regenerating
interleukin 22 (IL-22) production, and secretion of the protective mucous layer and
antimicrobial peptides (AMPs) by CECs. I3C in previous experiments has been shown to
help prevent colitis through induction of IL-22 via innate lymphoid type 3 cells (ILC3s).
In this study, we investigated how AhR deficiency in Rorc-expressing cells (which we refer
to as AR mice) affects anti-inflammatory immune response during I3C treatment of colitis,
whether I3C-AhR interaction in CECs increase IL-22 production during colitis, and the
effect of AhR deficiency on epigenetic modifications induced by I3C during colitis. A
dextran sodium sulphate (DSS) colitis mouse model was used in this study to mimic the
effects of ulcerative colitis and was introduced into drinking water and treatments of I3C
treatment were given. Results showed compared to wild-type (WT) AR mice induced with
colitis were unaffected by 13C treatment. In addition, the protective IL-22 production by
ILC3s was lost for the AR mice. Lastly, we show that I3C treatment does induce epigenetic
modifications (i.e. DNA methylation) in the promoter region of IL-22. Thus, we conclude
AhR knockout in Rorc-expressing immune cells mice resist the production of IL-22 via
ILC3s after I3C treatment during DSS-induced colitis, and loss of this potential protective
cytokine prevents I3C-mediated beneficial alterations in the gut microbiome.
important.2 There are two distinct forms of
colitis which are defined by the location of
the inflamed areas and by the depth of
lesions in the gastrointestinal tissue:
ulcerative colitis and Crohn’s disease.
Ulcerative colitis is known to cause
inflammation limited to the large

INTRODUCTION
Colitis is a disease characterized by
chronic inflammation in the digestive tract
and tissue annihilation within the intestinal
tract. Colitis can progress to form colon
cancer over a prolonged period, making
preventative treatments of colitis vitally
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intestine/colon, only reaching to the
superficial epithelial surface.3 Crohn’s
disease exhibits inflammation and typically
extends deeper into the colonic tissue
layers.4 The development of colitis is still an
ambiguous topic but is known to be
attributed to genetics, environmental
triggers such as diet, and dysregulation of
the luminal microbiota and immune
response.2
There are two different mouse
models for inducing colitis, each
representing a distinct form of colitis, using
dextran sodium sulfate (DSS) or 2,4,6trinitrobenzenesulfonic acid (TNBS).5 The
DSS induction provides as a model for
ulcerative colitis since DSS is toxic to
epithelial colon cells.5 The TNBS induction
portrays Crohn’s disease since it produces
an immune response.5 Both models are
known to exhibit the clinical symptoms of
weight loss, colon shortening, colon
damage, and diarrhea/bloody stool. This
experiment used the DSS colitis model.
Our lab recently published a report
using the TNBS model on female mice to
explore whether the compound I3C, a
naturally occurring plant product, can be
effective in preventing colitis and attempted
to identify the related mechanisms. 6 The
research uncovered that I3C mediates
inflammation by promoting the production
of the cytokine, interleukin-22 (IL-22). IL22 production is linked to the activation of
the aryl hydrocarbon receptor.6 These new
findings are expanded on in this paper since
this paper describes a nearly identical
experiment, except using the DSS model
and mice with AhR conditionally knocked
out in Rorc-expressing immune cells, which
are known to produce IL-22.
The aryl hydrocarbon receptor
(AhR) is a cytosolic-bound intracellular
receptor, meaning that the receptor is
located in the cytoplasm until activated by a
ligand.7 Once the ligand has bound to the

receptor, the receptor is able to translocate
to the nucleus, heterodimerizes with aryl
hydrocarbon receptor nuclear translocator
(ARNT) and mediate gene transcription of
AhR-responsive
genes.
The
gene
transcription mediation by the AhR receptor
helps regulate liver detoxification and
immune cell regulation.7 As a result, the
AhR receptor can be found in a variety of
cell types, including immune cells and
colonic epithelial cells.7 Interestingly,
previous research has discovered patients
suffering from colitis typically have a
decrease in expression of AhR in lamina
propia (LP) mononuclear cells. 8
I3C is a likely candidate for
treatment of colitis since it is a known
ligand for AhR.9 I3C already has a number
of known therapeutic advantages thus far,
such as anti-cancer, antioxidant, antimicrobial, and anti-inflammatory effects.10
I3C’s anti-inflammatory effects are thought
to be attributed to it driving IL-22
production, which promotes epithelial cell
regeneration and maintaining mucosal
barrier integrity.6 IL-22 can be expressed by
many cell types, including T helper cells
(Th17/Th22) and innate lymphoid Type 3
cells (ILC3).11 This experiment attempts to
determine the mechanism which I3C
undergoes when acting as an antiinflammatory agent by studying how AhR
deficiency in Rorc-expressing immune cells
(i.e. ILC3s) affects treatment of colitis.
There were six experimental groups used in
this experiment as a result: LM+Vehicle,
AR+Vehicle,
LM+I3C,
AR+I3C,
LM+Colitis, AR+Colitis, LM+Colitis+I3C,
and AR+Colitis+I3C.
This experiment is able to quantify
the number of IL-22 expressing immune
cells by conducting a staining panel for
labeling biomarkers distinct to T cells and
ILC3 cells; the lineage monoclonal
antibodies CD45+Lin-CD90.2+Rorgt are
indicative of ILC3 cells and CD4 for Th22.
iv

Since IL-22 production is already known to
be increased by I3C treatment, and I3C is
known to be related to DNA transcription
through AhR, this experiment also
examines the methylation patterns of
experimental mice. Increased methylation
indicates decreased transcription; decreased
methylation
indicates
increased
transcription. Thus, an increase in
methylated DNA would suggest a decrease
in AhR receptors or a decrease in 13C.
There is no definitive cure for colitis
and traditional drug treatments induce many
side effects. Glucocorticoids, for example,
can cause a variety of alterations in the liver
and pancreas.12 These patients are
recommended to have their blood checked
regularly by their doctor for signs of these
possible side effects. This study examined
blood samples from each experimental
mouse at the end of the trial, in order to
check for similar side effects.

facilities offered precise pathogen-free
conditions, with 12-hour light/12-hour dark
cycles.
This experiment required the use of
six distinct experimental groups. The
littermate mice (LM) served as controls in
comparison to the AR mice. The groups for
the experiment were LM+Vehicle,
AR+Vehicle,
LM+I3C,
AR+I3C,
LM+DSS, AR+DSS, LM+DSS+I3C, and
AR+DSS+I3C.
Generation of mice lacking AhR in Rorcexpressing cells (AR mice)
The
cre-flox
recombination
technique was used in our lab to generate
mice lacking AhR in Rorc-expressing
immune cells. AhR-floxed (AhRf/f) mice
were bred with Rorc(t)-cre mice to
produce AhR knockout (KO) mice in T
cells/ILC3s, named AR mice. Each mutant
transgene mouse was genotyped using PCR
to ensure the conditional deletion from
DNA, as seen in Figure 1. The DNA was
isolated from the tissue via tail snips (≤25
mg). The DNA was isolated from the tail
snips using the DNeasy Blood & Tissue Kit
(cat. nos. 69504 and 69506) from Qiagen.
Once the DNA was isolated, gel
electrophoresis was then used to validate
the mutant DNA using primers specific to
detect the mutant strains. TAE (triseacetate-EDTA) buffer (VWR) was used
with agarose (VWR) to create a standard
1.5% agarose gel. Approximately 1.5 g of
agarose was missed with 100 mL of TAE in
a microwaveable flask and then
microwaved for 1-3 minutes, or until the
agarose was completely dissolved. Once

METHODS
Animals
Male and female C57BL/6J mice
were purchased from Jackson Laboratory,
and experimental mice used were between
the age of 8 to 10 weeks, at the average
weight of 15-18 grams. The breeding pairs
included Ahr-flox (Ahrtm3.1Bra/J) bred
with a Rorc-cre (B6.FVB-Tg(Rorccre)1Litt/J). The mice were housed at the
Association
for
Assessment
and
Accreditation of Laboratory Animal Careaccredited (AAALAC-accredited) animal
facility in the University of South Carolina
School of Medicine, Columbia. The

Figure 1. Summary of experimental genotyping.
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cooled, approximately 2-3 𝜇l of ethidium
bromide (Sigma-Aldrich), EtBr, was added
to the mixture. Ethidium bromide would
bind to the DNA and was essential for
visualizing the DNA under ultraviolet (UV)
light. The mixture was then poured into the
casting tray of the gel box with the well
comb already in place. The poured gel was
then left to sit at room temperature for 2030 minutes, or until it had fully solidified.
Once solid, the agarose gel was placed in
the gel box, the gel box was filled to TAE
until the gel was covered, and a voltage
source was then attached to the electrodes.
The loading buffer, 1X TAE buffer (SigmaAlder) was added to each of the DNA
samples and the samples were then
carefully loaded into the wells of the gel.
The gel was run at 80-150 V for
approximately 1 hour. The electrodes were
removed, and the gel was carefully removed
from the gel box. The gel was placed under
a UV light (Universal Hood li Molecular
Imager with Camera, Bio-Rad) which
allowed for the DNA fragments to be
visualized. The control counterparts to the
mutant mice were controlled, or littermate
(LM), mice.

Induction of colitis and treatment with I3C
The DSS used for this experiment
was purchased from MP Biomedical LLC.
and was colitis grade. DSS model colitis
was induced in 4 of the experimental groups
through drinking water (Figure 2). The
drinking water contained 3% DSS for 6
days, which was followed by 8 days of
normal
drinking
water.
Previous
experiments have proven 1 week of DSS
treatment is sufficient for effectively
inducing an ulcerative colitis model. 13
There were 3 experimental groups who
received I3C treatment. For the treatment
groups with DSS colitis model, mice were
given injections of 40 mg/kg in 0.05%
DMSO/corn oil starting 1 hour after the
administration of the DSS water and
continued every other day until the end of
the experiment. LM groups were also given
0.05% DMSO/corn oil injections every
other day.
Assessment of colitis disease parameters
Clinical parameters for colitis were
measured and examined throughout the
entirety of the experiment. The mice were
weighed daily using a scale (ALC-2100.1,
Acculab), in order to determine the percent
weight loss over the duration of the trial.
Colonoscopies were also performed to
assess tissue damage. At experimental
endpoints, the mice were euthanized using
isoflurane overdose. After the trial
completion, the lengths of the colons were
measured. Serum (~10 microliters) was
analyzed using a VetScan (Allied Analytic)
to determine diagnostic blood panel
percentages, as outlined in Figure 3.

Figure 2. Summary of DSS colitis model with
I3C treatments. Colitis was induced using a DSS
model and the effectiveness of the I3C treatments
were tested with the following experimental groups
unless otherwise stated: LM vehicle (n=7), LM I3C
(n=5), LM DSS+vehicle (n=7), LM DSS+I3C
(n=7), AR DSS+vehicle (n=11), and AR DSS+I3C
(n=11).
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Figure 3. Summary of experimental method.

of the gentleMACS Dissociator (Miltenyi
Biotec) and the gentleMACS was run. Once
the program was complete, the tube was
detached from the Dissociator and a short
spin (up to 300xg) was completed in order
to collect the sample from the bottom of the
tube. Another 5 mL of complete RPMI
media (VWR) was added, and the cell
suspension was applied to a 100 𝜇m cell
strainer, inserted in a 50 mL tube. The 100
𝜇m strained was washed with 10 mL of PBS
with 3% FBS (FACS Buffer, VWR) and the
strainer was then discarded.
The cell suspension was centrifuged
at 1300 rpm for 10 minutes at 40oC. We
resuspended the cells in 10 mL of FACS
buffer and a layer on 5 mL of 90% Percoll,
having been diluted using 10x PBS (VWR).
The samples were then spun at 2000 rpm for
15 minutes at room temperature and
resuspended in 10 mL FACS. We spun the
samples again at 1300 rpm for 10 minutes
at 40oC and resuspended in 1 mL of RBC
lysis buffer on ice for 2 minutes. Once
chilled, 10 mL of FACS was added and the
samples were spun at 1300 rpm for 10
minutes at 40oC and resuspended in 2 mL of
FACS. An automated cell counter (BioRad) was used to record the cell count and
viability.
Once the cells were isolated from
tissue, they were stained with fluorescent
antibodies, indicators of IL-22-producing

Lamina propria layer isolation and immune
cell validation using flow cytometry
Flow cytometry was used to explore
the effects on immune cell response when
AhR was depleted in Rorc-expressing cells.
Cells from the lamina propria (LP) were
isolated by removing and cleaning the
intestine of a 6-10-week-old C57BL/6
mouse using PBS (VWR). The intestines
were placed into 50 mL conical tubes
(VWR) with 15 mL of pre-digestion buffer
(VWR) and incubated. The colons were
then cut laterally (~0.5 cm pieces) and
incubated for 40 minutes at 37oC under a
continuous rotation. Once incubated, the
samples were vortexed for 10 seconds and
applied onto a 100 𝜇m cells strainers
(VWR) having been placed on a 50 mL
tube. The samples were then transferred
into a new 50 mL tube containing 20 mL of
HBSS (VWR) and incubated at 37oC for 1020 minutes under a continuous rotation. The
samples were then vortexed for another 10
seconds to ensure they were mixed well and
applied onto a MACS SmartStrainer, 100
𝜇m, and placed in a 50 mL tube.
The intestine tissue was then
transferred into the gentle MCS C tube
which contained the digestion buffer and
the tube was sealed tightly. The sample was
then incubated again for 30-75 minutes at
37oC under continues rotation. The C tube
was the attached nupside down to the sleeve
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cells. The cells were then passed through
the FACS Celesta flow cytometer (BD
Biosciences). The gating and the analysis of
flow plots were performed using FlowJo
version 10.5.3 (BD Biosciences). Two
specific immune cells were stained in the
flow cytometry: ILC3 (CD45+LinCD90.2+Rorgt+) and Th22 (CD3+CD4+IL17-).
Determination of DNA methylation status
The DNA methylation patterns were
examined to determine the effects of I3C
treatments on transcription in the DSSmodel of ulcerative colitis. A genome-wide
DNA methylation was conducted using
methylated DNA immunoprecipitation
sequencing (MeDIP-seq) on cells isolated
from CD45+ immune cells from the lamina
propria
of
experimental
groups
(DSS+Vehicle and DSS+I3C). MeDIP-seq
was performed as previously described. 14
Statistics
All statistical analysis
were
conducted using GraphPad Prism software
unless otherwise indicated. A 1-way
ANOVA and Tukey’s hoc multiple
comparisons tests were used to determine
the statistical significance when comparing
3 or more groups. A 2-way ANOVA and
Turkey’s hoc multiple comparisons tests

were used to determine the statistical
significance when comparing 3 or more
groups with more than one data point. For
comparisons between only two groups, an
unpaired, 2-tailed standard Student’s t-test
was used. A P value less than 0.05 was
considered significant.
Study approval
All procedures conducted involving
the use of mice obey NIH guidelines under
protocols approved by the IACUC at the
University of South Carolina School of
Medicine (Columbia).
RESULTS
Treatment with I3C and/or DSS does not
effect blood work diagnostics
We conducted a full blood panel on
each of the mice at the end of the
experiment. The blood panel determined
the white blood cell (WBC) count and the
percent of lymphocytes, monocytes, and
neutrophils, as illustrated in Figure 4. The
white blood cell count provides
information on the immune system since
they aid the body to fight infection and
disease. Lymphocytes are what determine
the specificity of the immune response to
infection and disease. Monocytes aid other
WBC to remove dead or damaged tissues,

Figure 4. AhR defficiancy in Rorc-expressing immune cells resulted in no effect on blood work.
Blood was collected from experimental mice and run on a VetScan to access, White blood cell (WBC)
count, lymphocyte percent, monocyte percent, and neutrophil percent. Significance was determined using a
1-way ANOVA and Tukey’s multiple comparisons tests. There was found to be no significant differences
among the experimental groups when examining the blood diagnostics panel.
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kill cancer cells, and regulate immunity
from infection and disease. Neutrophils are
the first immune cells to respond to a
foreign pathogen and are responsible for
the destruction of the microorganism or
molecule.
Previous results from our have
proven that neither the I3C treatment does
not affect blood-circulated immune cells
like the white blood cell count and percent
of lymphocytes, monocytes, and
neutrophils, which play a role in the
immune response. To that end, we studied

mice with AhR deficiency in Rorcexpressing immune cell, in comparison to
the four control groups, and found no
statistically significant differences,
suggesting the major immune cell
differences are localized in the colon.
AR mice with I3C and DSS treatments
loose I3C-mediated beneficial effects
For the purpose of testing the
efficacy of I3C treatment in the DSS colitis
model, mice with colitis were treated with
an I3C regime that has been effective in

Figure 5. I3C treatment failed to protect against DSS-induced colitis in both AR mice. The
parameters assessed for quantifying the disease was (A) percent weight loss, (B) colon length, and (C)
Representative colonoscopy images were taken during day 7 of the DSS model (n=5). Scale bars: 100
micrometers (original magnification, x100). Significance was determined using a 1-way ANOVA and
Tukey’s multiple comparisons tests for the colon lengths and macroscopic colitis score and a 2-way
ANOVA and Tukey’s multiple comparisons tests for the percent weight loss; *P<0.05; **P<0.01;
***P<0.005; ****P<0.001.
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treating other forms of inflammatory
diseases.15 We used 6 experimental groups
of mice: vehicle alone (LM vehicle), I3C
treatments alone (LM I3C), diseased alone
(LM DSS+Vehicle), diseased receiving I3C
treatment (LM DSS+I3C), diseased mutant
(AR DSS+Vehicle), and diseased mutant
receiving I3C treatment (AR DSS+I3C).
The percent weight loss was determined
each day of the experiment from the start
(Figure 5A). We observed a significant
percent weight loss in the LM
DSS+Vehicle, the AR DSS+Vehicle, and
the AR DSS+I3C (Figure 5A). The percent
weight loss was slightly reduced for the LM
DSS+I3C (Figure 5A). Whereas, the LM
Vehicle and the LM I3C experienced no
significant weight loss (Figure 5A), which
suggested AR mice no longer responded to
I3C like the LM controls. Next, we
measured the colon lengths at the end of the
experiment (Figure 5B). Mice induced with

DSS colitis receiving I3C treatment
experienced a reduction in their colon
(~1.25 cm) compared to the control groups,
LM vehicle and LM I3C (Figure 5B). A
significant reduction in the colon lengths
were found in the LM DSS+Vehicle group
(~2.5 cm), the AR DSS+Vehicle group
(~3.0 cm), and the AR DSS+I3C group
(~2.5 cm). No statistical significant
difference was found in the colon lengths
between the diseased mutant mice and the
diseased mutant mice receiving treatment.
Colonoscopy images revealed that
the diseased mutant mice receiving
treatment had evidence of ulcerations and
tissue annihilation through the lining of the
colon, whereas the observations from the
diseased LM receiving treatment exhibited
far less destruction (Figure 5C). The
diseased vehicle mice, mutant diseased
mice, and the mutant diseased mice
receiving
I3C
treatment
displayed

Figure 6. IL-22 secretion by Th22 cells is unaffected in diseased AR mice. (A) Percent of IL22 producing Th22 cells. (B) Representative flow charts for each experimental group. Scale
bars: 100 micrometers (original magnification, x100). Significance was determined using a 1way ANOVA and Tukey’s multiple comparisons tests; *P<0.05; **P<0.01; ***P<0.005;
****P<0.001.
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significantly increased colon damage in
comparison to the controls, LM Vehicle and
LM I3C (Figure 5C). Taken altogher, it
appeared that AR mutants lost the ability to
respond to I3C treatment, unlike their LM
counterparts.

LM+DSS+I3C,
12.4
for
AR+DSS+Vehicle,
and
10.8
for
AR+DSS+I3C mice (Figure 6B). The
percent of IL-22 producing Th22 cell was
also determined for each experimental
group based off of the flow cytometry data.
We found no statistically significant
difference in the percent of Th22 cells
between the diseased AR mutant receiving
treatment and diseased LM mice receiving
I3C treatment (Figure 6A), thus suggesting
AhR on Rorc-expressing immune cells does
not alter IL-22 production by Th22 cells.

I3C-mediated increase of IL-22 secreted
by T cells is not altered in diseased AR
mice
The expression of IL-22 producing
Th22 cells in each experimental group was
determined using flow cytometry and
staining for CD4, a biomarker for T helper
cells. The percentages indicated in the
bottom left corner of each flow chart
provides a numerical value for comparison
of experimental groups based on levels of
CD4 expressing IL-22. The higher the
percentage, the greater the cells expression.
The flow charts depict LM+Vehicle mice
intensity as 3.58, 2.89 for LM+I3C, 14.6 for
LM+DSS+Vehicle,
11.4
for

I3C-mediated increase of IL-22 secreted
by ILC3 cells is prevented in diseased AR
mice
Flow cytometry was also used for
exploring whether the quantity of ILC3
cells in the lamina propria is affected by
AhR depletion in immune cells (AR mice).
The flow cytometer determined the percent
of IL-22 synthesizing ILC3s (Figure 7A)

Figure 7. IL-22 secretion by ILC3 cells is prevented in diseased AR mice. (A) Percent of IL-22
producing ILC3 cells. (B) Representative flow charts for each experimental group. Scale bars: 100
micrometers (original magnification, x100). Significance was determined using a 1-way ANOVA
and Tukey’s multiple comparisons tests; *P<0.05; **P<0.01; ***P<0.005; ****P<0.001.
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and revealed a representative bar chart
(Figure 7B). The representative bar charts
quantify the area of the shaded region, as
seen in the bottom right corner of each flow
plot. Thus, larger area values indicate an
increased number of IL-22 producing
ILC3s identified using the fluorescent
markers. The bar charts depict percent
quantification of the ILC3s (CD45+LinCD90.2+Rorgt+) producing IL-22.
It should be noted that the intensity
value indicated by the flow charts for
LM+Vehicle can be found as 20.6, 22.8 for
LM+I3C, 18.4 for LM+DSS+Vehicle, 65.3
for
LM+DSS+I3C,
20.9
for
AR+DSS+Vehicle,
and
27.2
for
AR+DSS+I3C mice (Figure 7B). The data
shows that in disease LM mice treated with
I3C there was a significant increase in IL22 production, which we had previously
shown. However, disease AR mice treated
with I3C did not show an increase in IL-22
production in ILC3 cells, which suggests
that this increase in protective IL-22 by this

immune cell subset was dependent on AhR
expression.
Treatment of I3C decreases methylation of
IL-22 promoter region in diseased mice
This experiment also sought to
begin
investigating
I3C-mediated
epigenetic modifications, DNA methylation
specfically, involved in IL-22 regulation.
The lab plans on exploring these epigenetic
modifications further in future studies with
AhR conditional knockout mice. DNA
methylation is of great significance since it
is relates to the frequency which the gene is
being transcribed. Samples from the two
diseased wild-type (WT) experimental
groups, WT DSS+Vehicle and WT
DSS+I3C, were used for MeDIP-seq, and
methylation patterns were determined for
the IL-22 promoter region of the DNA
(Figure 8). The DNA methylation of the
diseased mice receiving I3C treatment was
found to be significantly decreased in
comparison to the diseased mice not
receiving treatment. This suggests that one
of the mechanisms by which I3C increases
IL-22 production is by decreasing DNA
methylation in the promoter region for this
cytokine.
DISCUSSION
Research and new development of
safe preventative treatments to inhibit
colitis are of great importance. Studies have
shown chronic inflammation through the
intestine to be linked to alterations in the
luminal microbiota and to dysregulation of
the immune system.6 There is an increasing
consensus that AhR plays a prominent role
in regulating the immune system through
the intestine.16 AhR has been shown in
promote the production of interleukin-22
(IL-22) once activated by a ligand. 17
However, the mechanisms which AhR
primarily uses to regulate the immune
system in the gut microbiome is still

Figure 8. I3C decreases DNA methylation in
promoters of IL-22 regulatory genes during DSSinduced colitis. DNA methylation was determined
using MeDIP-seq, as described in the Methods. The
IL-22 promoter region can be found in the figure
highlighted green. The methylation patterns of
DSS+Vehicle (bottom) and DSS+I3C (top) samples
are displayed in the figure.
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unknown. There appears to be a link with
the expression of AhR in Rorc-expressing
immune cells that occur during colitis and
the expression of IL-22, which is
demonstarted further by this study.
The DSS-induced diseased mutant
AR mice lost all protective benefits of I3C
treatments. The diseased AR mice proved to
have no statistically significant difference
in their percent weight loss, colon lengths,
and macroscopic score when receiving I3C
treatment. Whereas, the diseased littermate
mice showed a significant improvement and
increase in their percent weight loss and
colon length when receiving I3C treatment.
The representative colonoscopy images
display the healing affects of I3C through
the colon when comparing the diseased LM
mice to the diseased LM mice receiving
treatment. However, the colonoscopy
images of the diseased mutant AR mice
receiving I3C treatment revealed evidence
of ulcerations and tissue destruction in the
lining of the colon, which was just as severe
as those found in the diseased mutant mice
not receiving treatment.
As noted before, I3C is a recognized
ligand of AhR. Recent reports have shown
I3C to have a protective effect by improving
the necroptosis and inflammation of
intestinal epithelial cells by activating AhR
in mice with DSS-induced colitis.18 In this
current study, AhR activation was
examined in Rorc-expressing immune cells.
There also has become an increasing
consensus that upon activation the AhR
receptor, there is an increased regulation of
IL-22,
helping
restore
the
gut
homeostasis.19 Thus, this study has further
proven that without an abundance of AhR
receptors, I3C has nothing to bind to, which
results in no production of IL-22, at least in
ILC3s. Similar reports have found ILC3s
production of IL-22 to change upon I3C
treatment.6

Of particular note was the fact that
secretion of IL-22 by ILC3 cells was
prevented in AR mutant mice receiving I3C
treatment. This was a important finding
because AhR can be found in many
different types of cells; however, it has
remained unclear as to which cell type
promotes
gastrointestinal
thereuputic
benefits via AhR activation. This study
revealed an increase in IL-22 secreting
ILC3 cells when diseased LM mice were
given I3C treatments. However, the
diseased mutant mice with a depletion of
AhR in Rorc-expressing immune cells
displayed no increase in IL-22 producing
ILC3 cells when receiving I3C treatments,
proving AhR was essential for this I3Cmediated effect.
In comparison, the T helper type 22
(Th22) cells were unaffected by a depletion
of AhR receptors. This would suggest that
the AhR receptor primarily use IL3C cells
over Th22 cells. We concluded that the AhR
receptor primarily translocates in ILC3 cells
when producing IL22. Other recent reports
have shown collectively that ILC3 cells are
responsible for regulating gastrointestinal
mucosal homeostasis via controlled
generation of IL-22 and IL-17.20
Interestingly enough, studies have also
shown the frequency of ILC3s to be
decreased in inflamed tissue.21
The methylation patterns of the
DSS-induced colitis diseased mice
recieving I3C treatment revealed a decrease
in methylation, when compared to the
diseased mice not receiving treatment. The
reduced methylation implies that there is a
increase in the transciption of the IL-22
gene. An increase in transciption would
result in an increase in creation of the
cytokine IL-22, which helps reduce and
control inflammation.22 Other reports have
recently suggested a protein coding gene,
the G Protein-Coupled Receptor 34, to be a
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receptor of ILC3 which triggers tissue
repair upon colon damage.23
The study’s findings are consistent
with the theory that DSS-induced diseased
mice when treated with I3C are able to
manage chronic inflammation and tissue
damage through production of IL-22. In
conclusion, these studies revealed that I3C

mediated protection against colitis was
heavily dependent on AhR expressed in
Rorc-expressing immune cells, such as
ILC3s. Without AhR expression, protective
IL-22 was no longer produced after I3C
treatment of colitis, thus negating the
beneifical effects observed in LM controls.

xiv
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